| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 3.9MM | +0% |
| Gross Profit | 440K | - |
| Cost Of Revenue | 3.5MM | -7% |
| Operating Income | -19.8MM | -0% |
| Operating Expenses | 20.2MM | +1% |
| Net Income | -19.1MM | -0% |
| R&D | 3.3MM | -7% |
| G&A | 8.4MM | +2% |
| Marketing | 8.4MM | +4% |
| Amortization | - | - |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
SAN DIEGO, April 18, 2024--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that the special committee of its board of directors engaged TD Cowen to conduct a process exploring strategic alternatives to maximize stockholder value. Potential strategic alternatives that may be explored or evaluated include an acquisition, merger, reverse merger, business combination, sale of assets, licens
SAN DIEGO, April 01, 2024--DermTech, Inc. (NASDAQ: DMTK) ("DermTech" or the "Company"), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that effective March 27, 2024, the Compensation Committee of DermTech’s Board of Directors granted an aggregate of 26,240 restricted stock units to eight new employees under its 2022 Inducement Equity Incentive Plan, as amended, or the 2022 Inducement Plan. The 2022 Inducement Plan is used exclusively for the
SAN DIEGO, March 08, 2024--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the presentation of two research abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting, taking place March 8th-12th in San Diego, California.
Shareholders in DermTech, Inc. ( NASDAQ:DMTK ) had a terrible week, as shares crashed 31% to US$0.87 in the week since...
DermTech, Inc. (NASDAQ:DMTK) Q4 2023 Earnings Call Transcript February 29, 2024 DermTech, Inc. misses on earnings expectations. Reported EPS is $-0.56 EPS, expectations were $-0.54. DMTK isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, thank you for […]
DermTech, Inc. (DMTK) delivered earnings and revenue surprises of -3.70% and 3.11%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
SAN DIEGO, February 29, 2024--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported its fourth-quarter 2023 financial results.
SAN DIEGO, February 13, 2024--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, will host a conference call and webcast on Thursday, February 29, 2024 at 5:00 p.m. Eastern Time (ET) to discuss the Company's fourth-quarter 2023 operating and financial results. In advance of the call on February 29, 2024, DermTech will issue its fourth-quarter 2023 earnings press release.
SAN DIEGO, January 31, 2024--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced additional restructuring actions to prioritize revenue growth, streamline operations and further reduce overall operating expenses.
SAN DIEGO, January 18, 2024--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported positive topline results from a study evaluating the foundational gene expression assay component of the DermTech Melanoma Test (DMT) across all skin types in the real-world clinical setting. The peer-reviewed study entitled, "Non-invasive gene expression analysis rules out melanoma with high negative predictive